Edition:
United States

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

25.39USD
23 Apr 2018
Change (% chg)

$1.53 (+6.41%)
Prev Close
$23.86
Open
$24.04
Day's High
$25.40
Day's Low
$24.00
Volume
125,483
Avg. Vol
68,228
52-wk High
$40.56
52-wk Low
$19.32

Latest Key Developments (Source: Significant Developments)

Reata Pharmaceuticals Inc. Announces Q4 Loss Per Share $0.64
Friday, 2 Mar 2018 07:30am EST 

March 2 (Reuters) - Reata Pharmaceuticals Inc ::REATA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS.Q4 LOSS PER SHARE $0.64.AS OF DECEMBER 31, 2017, COMPANY HAD $129.8 MILLION IN CASH AND CASH EQUIVALENTS.REATA PHARMACEUTICALS- BELIEVE EXISTING CASH AND CASH EQUIVALENTS, AVAILABLE DEBT AND EXPECTED MILESTONE WILL BE SUFFICIENT TO FUND INTO H2 2019.  Full Article

Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko
Thursday, 7 Dec 2017 05:20pm EST 

Dec 7 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK).REATA SAYS THIRD SUPPLEMENT ALLOWS CO TO BEGIN PORTION OF PHASE 3 CLINICAL STUDY OF RTA 402 IN FIELD OF ALPORT SYNDROME IN JAPAN - SEC FILING.REATA PHARMACEUTICALS - ON DEC 7 CO ENTERED FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO & KHK.  Full Article

Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​
Monday, 13 Nov 2017 09:18am EST 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc ::Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing.  Full Article

Reata Pharmaceuticals Q3 loss per share $0.50
Monday, 13 Nov 2017 07:30am EST 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results.Q3 loss per share $0.50.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Reata Pharmaceuticals Inc - qtrly ‍total collaboration revenue $12.6 million versus $12.6 million.Reata Pharmaceuticals Inc - ‍as of September 30, 2017, company had $154.6 million in cash and cash equivalents​.  Full Article

Reata Pharmaceuticals enters first amendment to loan and security agreement​
Tuesday, 7 Nov 2017 08:39am EST 

Nov 7 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals says ‍on November 3, co entered into a first amendment to loan and security agreement​ - SEC filing.Reata Pharmaceuticals Inc - ‍loan agreement was amended to increase amount of term B loan to $20 million prior to term B loan increase milestone​.Reata Pharmaceuticals Inc - ‍agreement was amended to increase amount of term B loan to $25 million following term B loan increase milestone​.  Full Article

Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​
Monday, 23 Oct 2017 07:30am EDT 

Oct 23 (Reuters) - Reata Pharmaceuticals Inc -:Reata Pharmaceuticals Inc - ‍announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich's Ataxia​.Reata Pharmaceuticals Inc - Reata expects top-line data to be available in second half of 2019 for omaveloxolone​ ‍​.  Full Article

Reata Pharma receives orphan drug designation for Omaveloxolone
Wednesday, 13 Sep 2017 05:26pm EDT 

Sept 13 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals Inc receives orphan drug designation for Omaveloxolone for the treatment of malignant melanoma.Reata Pharmaceuticals Inc - ‍FDA granted orphan designation to Omaveloxolone for treatment of stage IIb through IV malignant melanoma​.  Full Article

Reata Pharmaceuticals Q2 loss per share $0.52
Monday, 14 Aug 2017 04:01pm EDT 

Aug 14 (Reuters) - Reata Pharmaceuticals Inc :Reata pharmaceuticals Inc announces second quarter 2017 financial and operating results.Q2 loss per share $0.52.Q2 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S.  Full Article

FDA confirms use of mFARS as main goal in MOXIe trial can support omaveloxolone approval in Friedreich’s Ataxia
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Reata Pharmaceuticals Inc :FDA confirms that use of mFARS as primary endpoint in part 2 of the MOXIe trial can support approval of omaveloxolone in Friedreich’s Ataxia.Says ‍primary endpoint of trial will be change from baseline in mFARS of omaveloxolone compared to placebo at 48 weeks​.Reata Pharmaceuticals Inc says ‍initiated screening patients for part 2 of MOXIe and plans to randomize first patient during second half of 2017​.Reata Pharmaceuticals - ‍FDA indicated that it may consider either accelerated or full approval based on overall results of trial and strength of data​.Reata pharma- FDA recommended co extend treatment duration for part 2 of study, add a straightforward patient-reported or performance-based outcome endpoint.  Full Article

Reata announces first patient enrolled in Phase 3 Cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome
Monday, 7 Aug 2017 05:15pm EDT 

Aug 7 (Reuters) - Reata Pharmaceuticals Inc :Reata announces first patient enrolled in phase 3 cardinal trial of Bardoxolone Methyl in the treatment of chronic kidney disease due to Alport Syndrome.  Full Article

BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome

* REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME